Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: A global provider of innovative research tools for drug discovery, focusing on target validation, assay development, and ADMET (absorption, distribution, metabolism, elimination, and toxicology) screening. The company operates through a mix of proprietary manufactured products and distributed complementary products.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | 2001 | 2000 |
|---|---|---|
| Total Revenues | $40.9 million | $30.6 million |
| Cost of Product Revenues | $20.2 million | $15.8 million |
| Gross Margin | 50.8% | 48.4% |
| Operating Loss | $(4.7) million | $(10.4) million |
| Net Loss | $(5.2) million | $(49.9) million |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(6.25) |
| Cash and Cash Equivalents | $29.4 million | $35.8 million |
| Working Capital | $32.6 million | $40.6 million |
| Long-Term Debt | $0.6 million | $0.0 million |
| Stockholders' Equity | $66.8 million | $52.3 million |
Note: 2000 results were significantly impacted by a non-cash common stock warrant interest expense of $36.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 34% to $40.9 million, driven by acquisitions (approx. $4.0 million contribution) and organic growth from new product lines (spectrophotometers, plate readers).
- Profitability Improvement: Operating loss narrowed significantly from $(10.4) million to $(4.7) million. Net loss improved dramatically from $(49.9) million to $(5.2) million, primarily due to the elimination of the $36.9 million non-cash warrant interest expense recorded in 2000.
- Acquisition Activity: The company completed five major acquisitions in 2001 (Union Biometrica, Warner Instruments, Scie-Plas, Asys Hitech, and IMS), resulting in a $5.4 million charge for in-process research and development (IPR&D) and increased amortization of goodwill.
- Expense Increases: General and administrative expenses rose 35% and sales and marketing expenses rose 52%, largely attributable to the integration of acquired businesses and increased headcount.
- Liquidity: Cash balances decreased by $6.4 million due to significant investing activities ($20.2 million used for acquisitions and capital expenditures), partially offset by financing activities ($9.7 million provided) and operating cash flow ($4.1 million).
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects remaining IPO proceeds and operating cash flows to fund operations for the foreseeable future. The company plans to continue investing in R&D and pursuing strategic acquisitions.
- Accounting Changes: The company adopted SFAS No. 142 effective January 1, 2002, which will cease the amortization of goodwill (approx. $1.5 million annually) but requires annual impairment testing.
- Legal Contingencies:
- Harvard University Litigation: Harvard University sued for trademark infringement regarding the names "Harvard Bioscience" and "Harvard Apparatus." The court denied a preliminary injunction but restricted the use of the "Harvard" name in crimson or specific fonts. Management believes claims are without merit.
- Paul D. Grindle Arbitration: Former owner initiated arbitration seeking return of stock or $15 million in damages related to a 1996 asset purchase. Management intends to defend vigorously, citing statutes of limitation.
- Key Risks:
- Customer Concentration: Amersham Biosciences accounted for approximately 30% of 2001 revenues. The distribution agreement is critical and could be terminated with notice.
- Foreign Currency: Approximately 60% of revenues are from non-U.S. operations. A stronger U.S. dollar in 2001 reduced reported revenue growth.
- Intellectual Property: Reliance on patents and trade secrets; risk of infringement claims or inability to protect proprietary technology.
Investor Verification Checklist
- Amersham Biosciences Dependency: Verify the stability of the distribution agreement with Amersham Biosciences, which represents 30% of revenue.
- Acquisition Integration: Assess the financial performance and integration progress of the five 2001 acquisitions, particularly Union Biometrica (COPAS technology).
- Legal Exposure: Monitor the status of the Harvard University trademark lawsuit and the Paul D. Grindle arbitration for potential financial impact or brand restrictions.
- Goodwill Valuation: Review the upcoming annual impairment test for the $24 million in goodwill and indefinite-life intangibles under SFAS 142.
- Foreign Exchange Sensitivity: Evaluate the impact of currency fluctuations on future earnings given the 60% international revenue mix.